NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Phone239-768-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$258.61 million
Profitability
Miscellaneous
Employees1,030
OptionableOptionable
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The medical research company earned $69.10 million during the quarter, compared to the consensus estimate of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. The company's quarterly revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 EPS. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $0.17-0.19 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $266.88 million, compared to the consensus revenue estimate of prior $0.12-0.17.
What price target have analysts set for NEO?
10 analysts have issued 1 year target prices for NeoGenomics' shares. Their forecasts range from $14.00 to $24.00. On average, they expect NeoGenomics' stock price to reach $19.8182 in the next year. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
What are Wall Street analysts saying about NeoGenomics stock?
Here are some recent quotes from research analysts about NeoGenomics stock:
- 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (1/8/2019)
- 2. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)
Has NeoGenomics been receiving favorable news coverage?
Media stories about NEO stock have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NeoGenomics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting NeoGenomics?
NeoGenomics saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,262,837 shares, an increase of 42.7% from the December 14th total of 2,987,331 shares. Based on an average trading volume of 1,342,008 shares, the short-interest ratio is currently 3.2 days. Approximately 4.9% of the shares of the company are sold short. View NeoGenomics' Current Options Chain.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Charles River Laboratories Intl. (CRL), STADA Arzneimittel (STDAF), HYPERA S A/S (HYPMY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), athenahealth (ATHN), Premier (PINC), Alkermes (ALKS), Haemonetics (HAE), Catalent (CTLT), Syneos Health (SYNH), United Therapeutics (UTHR), GN STORE NORD A/ADR (GNNDY), ORION OYJ/ADR (ORINY) and ELEKTA AB/ADR (EKTAY).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)
- Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 48)
- Dr. Steven G. Brodie, VP of Worldwide Pharma Services Operations (Age 58)
- Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.55%), Fulton Bank N.A. (0.05%) and Fox Run Management L.L.C. (0.02%). Company insiders that own NeoGenomics stock include Alison L Hannah, Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and Fulton Bank N.A.. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Robert J Shovlin, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah and Kevin C Johnson. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $15.82.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $1.45 billion and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
What is NeoGenomics' official website?
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
